Historically, these men would undergo PSA testing generally every six months, followed by random 12-core transrectal ultrasound biopsies, usually one to two years after diagnosis, and further biopsies performed when clinical suspicion of prostate cancer increased, generally due to rising PSA [2,3,34]. The gene discussed is KLK3; the disease is prostate cancer.